Please note. Investigational: not approved by the FDA. Information is for clinical and research awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Mifamurtide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages.
Mifamurtide
Not approved by the FDA. Being tested in clinical trials (furthest: Phase 2).
Tested in at least one proper controlled study in people, with results.
There is no FDA-approved product with this peptide.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Tested in at least one proper controlled study in people, with results.
Not FDA-approved. In clinical trials (highest phase: Phase 2); 4 trial(s) listed on ClinicalTrials.gov, led by UNICANCER, Anna Raciborska.
Last verified: Nov 11, 2026
Share your pre-launch perspective on Mifamurtide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
